TELO — Telomir Pharmaceuticals Share Price
Last trade - 00:00- $111.04m
- $107.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 51.53 | ||
| Price to Tang. Book | 51.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -426.32% | ||
| Return on Equity | -1249.34% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Telomir Pharmaceuticals, Inc. is a United States-based company. The Company operates as pre-clinical-stage pharmaceutical company focused on developing TELOMIR-1 small molecule to lengthen the deoxyribonucleic acid’s (DNA) protective telomere caps to affect age reversal. It selectively affects the processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 26th, 2021
- Public Since
- February 9th, 2024
- No. of Shareholders
- 70
- No. of Employees
- 1
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 29,609,814
- Address
- 900 West Platt Street, Suite 200, TAMPA, 33606
- Web
- https://telomirpharma.com/
- Phone
- +1 8138642562
- Auditors
- Cherry Bekaert LLP
Similar to TELO
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
As of Today at 17:41 UTC, shares in Telomir Pharmaceuticals are trading at $5.25. This share price information is delayed by 15 minutes.
Shares in Telomir Pharmaceuticals last closed at $5.25 and the price had moved by over the past 365 days. In terms of relative price strength the Telomir Pharmaceuticals share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Telomir Pharmaceuticals does not currently pay a dividend.
Telomir Pharmaceuticals does not currently pay a dividend.
Telomir Pharmaceuticals does not currently pay a dividend.
To buy shares in Telomir Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.25, shares in Telomir Pharmaceuticals had a market capitalisation of $155.45m.
Here are the trading details for Telomir Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TELO
Based on an overall assessment of its quality, value and momentum Telomir Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Telomir Pharmaceuticals. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $5.25, shares in Telomir Pharmaceuticals were trading -23.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Telomir Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Telomir Pharmaceuticals' directors